Relay Therapeutics Q3 2026 Results: Net Loss of $81.7M, Loss Widens
Relay Therapeutics is a large accelerated filer with 220,959,470 shares of common stock outstanding as of October 30, 2026. The company remains a clinical-stage biopharmaceutical firm with no product revenue, incurring significant operating losses while focusing on the development of its precision medicine pipeline.
- Key figure
- Net loss $81.7M